Primer on Cancer Immunology and Immunotherapy

When:  Sep 21, 2017 from 08:15 to 12:00 (ET)

Presented by Weill Cornell Medicine, in collaboration with the Society for Immunotherapy of Cancer

The Primer on Cancer Immunology and Immunotherapy is part of the International Conference on Immunotherapy Radiotherapy Combinations on September 21 – 23, 2017.

International Conference on Immunotherapy Radiotherapy Combinations

The importance of immunology in tumor response to radiotherapy represents a major opportunity for the field. Combinations of immunotherapies and radiotherapy have the potential to translate into both better local tumor control rates and better distant control given the possibility to use radiotherapy as an immunological enhancer of the anti-tumor immune response. This conference will address the selection of optimal treatment combinations, the use of biomarkers for patient selection, and the creation of innovative clinical trial designs.

Primer on Cancer Immunology and Immunotherapy

The first morning of the conference consists of a Primer on Immunology and Immunotherapy, which offers CME credits. The primer will provide a basis for understanding the role of the immune system in cancer, the application of common usages of immunotherapy to clinical practice, and promising treatment applications under development. Participation in the primer is included with registration for the full conference.

This activity is intended for physicians, physician assistants, and translational, basic and clinical scientists engaged in the treatment of cancer.

Register for the program and find more information HERE (including fee information). 

Educational Objectives

Upon completion of this activity, attendees will be able to:

  • Describe the role of the immune system in tumor development and progression
  • Describe the role of innate and adaptive immunity in response to immunotherapy
  • Explain the barriers in the tumor microenvironment to tumor rejection
  • Appropriately use currently approved immunotherapies in clinical practice
  • Provide an overview of immunotherapy agents in development
  • Explain the various cancer immunotherapy options to patients

Primer Agenda

Primer Chair

Sandra Demaria, MD – Weill Cornell Medical College

Session I: Basic Immunology

8:30 – 9 a.m.

Introduction to Innate Immunity
A. Karolina Palucka, MD, PhD – The Jackson Laboratory for Genomic Medicine

9 – 9:30 a.m.

Overview of Adaptive Immunity
Alan Frey, PhD – New York University School of Medicine

Session II: Tumor Immunology

9:30 – 10 a.m.

Role of the Immune System in Tumor Development and Progression
Charles Drake, MD, PhD – Columbia University Medical Center

10 – 10:30 am

Coffee Break

10:30 – 11 a.m.

Barriers to Tumor Rejection in the Tumor Microenvironment

Session III: Cancer Immunotherapy

11 – 11:30 a.m.

Overview of the Immunotherapy Landscape
Michael Postow, MD – Memorial Sloan Kettering Cancer Center

11:30 am – noon

Immunotherapies in the Horizon
Robert Vonderheide, MD – University of Pennsylvania

noon – 1 p.m.


Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

PIM Logo SITC Logo
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer

#CME #SITC #CollaborativeEvent #Industry #InpersonEvent #2017 #Collaboration #Researcher #CombinationTherapy


Weill Cornell Medical College
New York, NY 10065